Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK “Sincerely Apologizes” And Accepts Record $485 Million Fine For China Bribes

This article was originally published in PharmAsia News

Executive Summary

The ticket has finally been handed out. Amid a record fine for bribery, GSK says that it remains fully committed to China.

You may also be interested in...



GSK Revamps Sales Reps Incentives To Be Competitive In Cancer

Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.

China Drug Price Negotiations: Another Race To The Bottom?

With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?

China Closes In On Top 10 In Global Innovation Ranking

China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC088193

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel